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Abstract
To investigate the biologic relevance and clinical implication of genes involved in multiple
gene expression signatures for breast cancer prognosis, we identified 16 published gene
expression signatures, and selected two genes,MAD2L1 and BUB1. These genes
appeared in 5 signatures and were involved in cell-cycle regulation. We analyzed the
expression of these genes in relation to tumor features and disease outcomes. In vitro
experiments were also performed in two breast cancer cell lines, MDA-MB-231 and MDA-
MB-468, to assess cell proliferation, migration and invasion after knocking down the expres-
sion of these genes. High expression of these genes was found to be associated with
aggressive tumors and poor disease-free survival of 203 breast cancer patients in our
study, and the association with survival was confirmed in an online database consisting of
914 patients. In vitro experiments demonstrated that lowering the expression of these
genes by siRNAs reduced tumor cell growth and inhibited cell migration and invasion. Our
investigation suggests that MAD2L1 and BUB1 may play important roles in breast cancer
progression, and measuring the expression of these genes may assist the prediction of
breast cancer prognosis.
Introduction
Accurately predicting the prognosis of breast cancer remains a significant challenge [1]. Many
clinical, pathologic and molecular markers have been identified for breast cancer prognosis,
including disease stage, tumor grade and histology, lymph node involvement, hormone/growth
factor receptor status and recently molecular subtypes, but none of them provides ideal accu-
racy in predicting prognosis and treatment response. High-throughput analyses, based on
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microarray chips and other technologies, are used to determine gene expression “signatures”
for improved accuracy of prognosis. The first such signature was reported in 2002, which was
on based on the expression of 70 genes using a DNA-microarray technology [2]. Since then,
more than a dozen of gene expression signatures have been published for breast cancer progno-
sis [3–15]. Interestingly, when comparing the genes in the signatures, only a small number
are shared by these signatures, and most of the genes are not overlapping. Reasons for this
disparity in gene lists are probably multiple, including diverse patient populations, disease
characteristics, analytical technologies, tissue preservation and preparation methods, and some
degree of false positivity. Because of the inconsistency of gene inclusion across signatures as
well as the feasibility and cost of using such signatures in patient management, many of the
expression signatures have not been confirmed in prospective studies. To date, only two prog-
nostic signatures [2, 16] are being evaluated in clinical trials for utility [17, 18], but the results
will not be available until 2020.
While many studies are still aiming to develop new methods and techniques to improve the
accuracy of prediction with the use of gene signatures, the biological relevance or pathologic
involvement of the genes in signatures are often overlooked. Usually, the genes in a signature
involve a number of biological processes and functions, making it difficult to identify key
components that may drive tumor progression. For example, the first 70-gene signature [2]
contains genes involved in multiple biological activities, including cell cycle regulation, cell
invasion and metastasis, angiogenesis, and signal transduction. Which process play key roles in
tumor progression is unclear. Furthermore, the effects on tumor cells of many genes in the sig-
natures are unknown. Thus, in an attempt to address some of these issues, we identified and
compared genes from 16 publications that have reported gene-expression signatures for breast
cancer prognosis. From the genes that appeared in multiple expression signatures, we selected
two,MAD2L1 (Mitotic Arrest Deficient 2-like 1) and BUB1 (Budding Uninhibited by Benz-
imidazoles 1), for further validation of their associations with patient survival in our own and
other studies, as well as for in vitro evaluation of their biological involvements in breast cancer.
Material and Methods
Selection of gene expression signatures
We searched the PubMed database (US National Library of Medicine) using the phrases
“breast cancer”, “gene expression”, “signature”, and “survival”. The search was updated in May
2015. The studies selected for our analysis were based on the following conditions: a) it was an
initial report of a gene signature associated with breast cancer survival; b) an entire list of genes
involved in the signature was reported; and c) gene expression data were generated from
microarray analysis. Following the criteria, a total of 14 studies (or signatures) were selected
[2–15, 18, 19]. Two additional studies by van Vliet et al. [20] and Dai et al. [21] were also
included in our analysis. These studies analyzed the same data from Van’s Veer [2], but used
very different strategies and generated different signatures with regard to the lists of genes.
Therefore, they were considered as independent studies. The study conducted by Van’s Veer
et al [2] identified a 231-gene signature in the initial stage. We used the genes in the initial sig-
nature for our analysis. A well-known EndoPredict signature based on RT-qPCR analysis was
also included in our study [12].
Breast cancer patients
We recruited 203 female patients diagnosed with primary breast cancer from the University
Hospital at University of Turin between January 1998 and July 1999. The patients were
enrolled in the study before surgery and were followed through February 2007. The study was
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approved by the ethical review committee of University Hospital at University of Turin. All
participants provided written informed consent. Fresh breast tumor samples removed during
surgery were snap-frozen in liquid nitrogen immediately after resection and stored at -80°C
until analysis. Clinical and pathological characteristics of the patients are shown in the result
section.
RNA extraction and analysis
Protocols for RNA extraction and gene expression analysis have been described elsewhere [22].
Briefly, total RNA was extracted from fresh-frozen tumor samples according to the conven-
tional phenol-chloroform method following manual pulverization of tissue specimens in liquid
nitrogen. The RNA samples were purified and concentrated by RNeasy MinElute Cleanup Kit
(Qiagen Inc., Valencia, CA). Concentrations and integrities of total RNA were analyzed using
the RNA 6000 Nano LabChip Kit and Agilent 2100 Bioanalyzer. Microarray analyses were per-
formed using the Illumina Expression BeadChip (HumanRef-8 v3) following the manufactur-
er’s protocol.
Antibodies
Antibodies used for western blot analysis were purchased from various companies. Anti-
MAD2L1 (D8A7, #4636) antibody and horseradish peroxidase (HRP)-conjugated secondary
antibody were purchased from Cell Signaling Technology (Danvers, MA), anti-BUB1 antibody
(ab54893) was from Abcam (Cambridge, MA), and anti-β-actin antibody (A2228) was from
Sigma-Aldrich (St. Louis, MO).
Cell lines and cultures
Human breast cancer cell lines MDA-MB-231 (MB231) and MDA-MB-468 (MB468) used for
our in vitro experiments were supplied by Dr. Richard Yip at University of Hawaii Cancer Cen-
ter, who obtained them from NCI as part of the NCI-60 DTP Human Tumor Cell Screening
Panel. The cells were cultured in Dulbecco's Modified Eagle Medium (DMEM) supplemented
with 10% fetal bovine serum (FBS) and 100 units/ml of penicillin/streptomycin (Pen/Strep) at
37°C in a humidified atmosphere of 5% CO2.
Western blots
In siRNA knockdown experiments, protein expression was analyzed by western blot. Cells
were treated with a lysis buffer [1% Triton x-100, 150 mMNaCl, 50 mM Tris-Cl, pH 7.4,
0.5 mM EDTA, 1 mM sodium orthovanadate, 5 mM beta glycerol phosphate, and 1x protease
inhibitor cocktail (Roche, Indianapolis, IN)] after transfection with indicated siRNAs for 36 h,
and protein concentration was measured. Proteins (40–60 μg) from the cell lysates were sepa-
rated by SDS-PAGE (10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis) under
denaturing conditions, and then transferred to polyvinylidene difluoride (PVDF) membranes
(Millipore, Billerica, MA). After transferring, the membranes were blocked with 5% non-fat
milk for 45 minutes, and then incubated with a primary antibody followed by incubation with
a secondary antibody. The signals were detected by the enhanced chemiluminescence system
(ECL) as described by the manufacturer (Pierce, Rockford, IL).
siRNA transfection
The ON-TARGET plus SMARTpool siRNA of humanMAD2L1 and BUB1 and negative con-
trol ON-TARGET plus Non-targeting Pool were purchased from Dharmacon (Lafayette, CO).
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The sequences ofMAD2L1 and BUB1 siRNAs as well as control siRNAs are (a) ON-TARGET
plus SMARTpool HumanMAD2L1 siRNA: UUACUCGAGGCAGAAAUA (siMAD2L1-1),
CUACUGAUCUUGAGCUCAU (siMAD2L1-2), GGUUGUAGUUAUCUCAAAU
(siMAD2L1-3) and GAAAUCCGUUCAGUGAUCA (siMAD2L1-4); (b) ON-TARGET plus
SMARTpool Human BUB1 siRNA: CGAAGAGUGAUCACGAUUU (siBUB1-1), CAAAGA
AGGGUGUGAAACA (siBUB1-2), GAAUGUAAGCGUUCACGAA (siBUB1-3), and GCAA
CAAACCAUGGAACUA (siBUB1-4); and (c) ON-TARGET plus Non-targeting siRNA: UGG
UUUACAUGUCGACUAA (siRNA-1), UGGUUUACAUGUUGUGUGA (siRNA-2), UGGU
UUACAUGUUUUCUGA (siRNA-3), and UGGUUUACAUGUUUUCCAU (siRNA-4). Cells
were seeded onto 6-well plates in antibiotic-free medium plus 10% FBS overnight. When 70%
confluent, cells were transfected with Lipofectamine RNAiMAX (Invitrogen) according to the
manufacturer’s protocol. The final concentration of siRNAs was 50 nM. After transfection,
cells were cultured for 36 hours, and then analyzed by western blot for protein expression of
MAD2L1 and BUB1, as well as cell proliferation, in vitromigration and invasion assays.
Cell proliferation assay
Cells were plated onto 96-well plates at a density of 3 x 103 cells per well, and cultured in the
complete medium at 37°C under a humidified atmosphere containing 5% CO2. At 0, 24, 48,
and 72 hours of incubation, cell proliferation reagent WST-1 was added into the wells in accor-
dance with the manufacturer’s instructions (Roche, Penzberg, Germany). Cells were continu-
ously incubated for 2 hours with WST-1, and then the color in each well of the plate was
measured by a microplate spectrophotometer (Biotek Synergy 2, Winooski, VT) at the 450 nm
wavelength. The light absorbance was proportional to the numbers of cells in each well. The
results of measurement at different time points of incubation were referenced to the measure-
ment at 0 hours of incubation. Each proliferation assay was performed in triplicate.
Transwell migration and invasion assays
In vitro cell migration and invasion assays were performed in 24-well plates with the Costar
Transwell permeable membrane support with 8.0-μm pore size (Corning, NY). In the cell inva-
sion assay, 200 μl control and siRNA knockdown cells in serum-free medium (1 x 104 cells per
well) were seeded in the upper chambers coated with growth-factor-reduced Matrigel, 1 mg/ml
(BD Pharmingen, San Diego, CA). The lower chambers were filled with 600 μl culture medium
containing 10% FBS. Cell migration assays were performed similarly but without Matrigel coat-
ing. Cells invading or migrating to the underside of the filter membrane were stained with
HEME 3 Solution (Fisher Diagnostics, Middletown, VA) after 36 hours of culture, and then
counted using an Olympus CKX41 microscope with an Infinity 2 camera. All experiments
were repeated three times with triplicate wells.
Statistical analysis
DAVID Bioinformatics Resources v6.7 (http://david.abcc.ncifcrf.gov) was used for the pathway
enrichment analysis, with recommended standard parameters selected in the analysis [23, 24].
KEGG (Kyoto Encyclopedia of Genes and Genomes) database (http://www.genome.ad.jp/
kegg/) was employed for the analysis of protein functions in different pathways. All the micro-
array data were pre-processed by the BeadStudio Software and analyzed using the R statistical
software and Bioconductor [25]. The Lumi R package was used to normalize the data [26].
Wilcoxon rank-sum test was performed to assess the association of gene expression and clini-
copathologic characteristics of breast cancer patients. Kaplan-Meier survival analysis and Cox
proportional hazards regression models were used to analyze the association of gene expression
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with breast cancer survival. Log-rank test was performed for Kaplan-Meier survival curve com-
parisons. Hazards ratios (HRs) and 95% confidence intervals (CIs) were calculated in the
Cox regression analysis, and both univariate and multivariate models were developed. In multi-
variate analysis, HRs were adjusted for patient age at surgery, tumor grade, disease stage, and
estrogen receptor (ER) and progesterone receptor (PR) status. Two types of survival outcomes
were considered in survival analysis, overall survival (OS) defined as the time between the date
of surgery and date of death or last follow-up, and relapse-free survival (RFS) defined as the
period from surgery to recurrence or last follow-up.MAD2L1 and BUB1 expression were cate-
gorized into low, medium and high based on their tertile distributions. To validate the associa-
tions ofMAD2L1 and BUB1 expression with breast cancer survival, an online tool named Gene
expression-based Outcome for Breast cancer Online (GOBO) (http://co.bmc.lu.se/gobo) was
used [27]. All of the values presented in the figures of in vitro experiments are means and stan-
dard deviations. Two-tailed Student t test was performed to determine the differences in means
between groups, and P<0.05 was considered statistically significant. All statistical analyses
were performed using the Statistical Analysis System, version 9.2, (SAS Institute Inc., Cary,
NC) and R software (version 3.0.2).
Results
Genes in 16 reported expression signatures
Studies reported gene expression signatures in association with breast cancer prognosis are
listed in S1 Table. These signatures included a total of 1,399 distinct genes. Of them, 1,138
were found to have official names. One gene, BIRC5 (also known as Survivin), was included in
7 signature lists, another,MYBL2, was in 6 lists, 5 genes (BUB1, CENPF,MAD2L1, RRPM2,
PRC1) were in 5 lists, and 12 genes were in 4 lists. The complete list of genes appearing in 3
or more signature lists is provided in S2 Table. Using the DAVID Bioinformatics Resources
v6.7 to analyze the 1,138 genes for pathway enrichment, we found four significantly enriched
pathways. Cell cycle was the most significant one (Benjamini-Hochberg corrected p = 10−9.5),
followed by p53 signaling pathway (p = 10−4.2), pathways in cancer (p = 10−3.6), and DNA
replication (p = 0.016). We found that three genes involved in multiple signatures were also
associated with survival outcomes in our study, including MAD2 mitotic arrest deficient-like 1
(MAD2L1), pituitary tumor-transforming gene-1 (PTTG1), and budding uninhibited by benz-
imidazole 1 (BUB1). All of these genes were involved in the cell cycle pathway. Since the effects
of PTTG1 on breast cancer cells have been studied previously by Yoon at el. [28], we focused
our analyses onMAD2L1 and BUB1.
Associations ofMAD2L1 and BUB1 expression with clinical and
pathologic features
Using the gene expression data from our microarray analysis of breast cancer [22], we exam-
ined the associations ofMAD2L1 and BUB1 expression with tumor features and disease out-
comes. Table 1 shows the clinical and pathologic characteristics of breast cancer patients in
association withMAD2L1 and BUB1 expression. Patients with PR negative, ER negative, and
high grade tumors had higher expression ofMAD2L1 and BUB1 compared to those with PR
positive, ER positive, and low grade tumors, respectively. Patient age, disease stage and lymph
node involvement were not associated withMAD2L1 or BUB1 expression.
To evaluate whetherMAD2L1 and BUB1 are over-expressed in breast cancer, a dataset
(GSE37751) was downloaded from the Gene Expression Omnibus (GEO) website (www.ncbi.
nlm.nih.gov/geo). This dataset included gene expression data from 61 breast cancer and 47
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adjacent non-tumor tissues analyzed by the GeneChip Human Gene 1.0 ST arrays (Affymetrix,
Santa Clara, CA). The expression data were processed by the RMA algorithm using the Affy-
metrix Expression Console software [29]. BothMAD2L1 and BUB1 expression were found to
be higher in tumor than in adjacent non-tumor tissues (5.97±0.66 versus 5.36±0.38 for
MAD2L1, 6.80±1.14 versus 5.50±0.74 for BUB1, respectively, and both P<0.0001) in this data-
base. Similar differences were also observed in another GEO dataset (GSE29044) [30].
Associations ofMAD2L1 and BUB1 expression with overall and relapse-
free survival
We further investigated the associations ofMAD2L1 and BUB1 expression with breast cancer
survival. Fig 1 shows that high expression ofMAD2L1 was significantly associated with
increased risk of disease recurrence and death. Patients with high tumor expression of BUB1
also had poorer relapse-free and overall survival compared to those with low tumor expression.
The associations ofMAD2L1 and BUB1 expression with relapse-free survival remained statisti-
cally significant after adjusting for age at surgery, ER and PR status, tumor grade, and disease
stage (Table 2). The relationships of breast cancer survival withMAD2L1 and BUB1 expression
were also analyzed in the GOBO database consisting of 914 tumor samples from 11 publically
available microarray datasets. The results of the GOBO database analysis were similar to the
findings of our study. High expression ofMAD2L1 and BUB1 were significantly associated
with poor relapse-free survival (Fig 2B and 2D). HighMAD2L1 expression was also associated
with poor overall survival (Fig 2A).
Table 1. Associations ofMAD2L1 and BUB1 expression with clinical andmolecular characteristics of breast cancer.
Variables MAD2L1 BUB1
Low No. (%) Middle No. (%) High No. (%) P Low No. (%) Middle No. (%) High No. (%) P
Age at surgery 0.375 0.113
57.11 35(34.31) 30(29.42) 37(36.27) 37(36.27) 27(26.48 38(37.25)
>57.11 33(32.35) 39(38.24) 30(29.41) 31(30.39) 41(40.20) 30(29.41)
Estrogen receptor 0.027 0.00036
Positive 47(37.01) 47(37.01) 33(25.98) 52(40.94) 45(35.43) 30(23.62)
Negative 21(27.27) 22(28.57) 34(44.16) 16(20.78) 23(29.87) 38(49.35)
Progesterone receptor 0.012 0.000002
Positive 42(41.18) 36(35.29) 24(23.53) 49(48.04) 34(33.33) 19(18.63)
Negative 25(25.51) 32(32.65) 41(41.84) 18(18.37) 33(33.67) 47(47.96)
Lymph node status 0.254 0.662
Positive 31(31.31) 39(39.39) 29(29.29) 30(30.30) 35(35.35) 34(34.34)
Negative 37(35.24) 30(28.57) 38(36.19) 38(36.19) 33(31.43) 34(32.38)
Grade 0.000001 < .000001
1 18(69.23) 4(15.38) 4(15.38) 15(57.69) 7(26.92) 4(15.38)
2 29(37.18) 33(42.31) 16(20.51) 38(48.72) 25(32.05) 15(19.23)
3 20(20.41) 31(31.63) 47(47.96) 13(13.27) 36(36.73) 49(50.00)
Disease stage 0.237 0.093
I 28(42.42) 22(33.33) 16(24.24) 26(39.39) 26(39.39) 14(21.21)
II 34(30.63) 36(32.43) 41(36.94) 36(32.43) 34(30.63) 41(36.94)
III, IV 6(22.22) 11(40.74) 10(37.04) 6(22.22) 8(29.63) 13(48.15)
doi:10.1371/journal.pone.0136246.t001
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Suppression ofMAD2L1 and BUB1 expression in breast cancer cell
lines
To evaluate the biological effects of MAD2L1 and BUB1 on breast cancer, we designed two
RNA interference (RNAi) assays to knockdown the expression ofMAD2L1 or BUB1. The
experiments were performed in two triple-negative breast cancer cell lines MDA-MB-231 and
MDA-MB-468, which had high expression of endogenousMAD2L1 and BUB1. Cell growth,
invasion and migration were evaluated in our in vitro experiments. Western blot analyses
showed that MAD2L1 and BUB1 proteins were significantly declined after the cells were trans-
fected with siRNAs specific forMAD2L1 or BUB1 (Figs 3 and 4). Compared with those trans-
fected with scrambled siRNA, cells withMAD2L1 or BUB1 siRNA had lower cell proliferation.
Cell invasion and migration were also reduced in those treated withMAD2L1 or BUB1 siRNA.
Taken together, these results suggest that lowMAD2L1 or BUB1 expression may inhibit breast
cancer cell proliferation, invasion, and migration.
Fig 1. Kaplan-Meier survival curves by different levels ofMAD2L1 andBUB1 expression in 203 breast cancer patients. A) Overall survival (OS) by
low, medium and highMAD2L1 expression; B) Relapse-free survival (RFS) by low, medium and highMAD2L1 expression; C) Overall survival (OS) by low,
medium and high BUB1 expression; (D) Relapse-free survival (RFS) by low, medium and high BUB1 expression.
doi:10.1371/journal.pone.0136246.g001
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Discussion
More than a dozen gene expression signatures involving over 1,300 genes have been published
for breast cancer prognosis. Among them, no single gene was included in all of the signatures,
and only two genes (MYBL2, BIRC5) were shared by six or seven signatures. These genes were
reported to be associated with breast cancer survival, and suppressing the expression of these
genes inhibited tumor cell proliferation [31, 32]. Five genes appeared in five signatures, and
twelve genes in four signatures. This low frequency of genes overlapping in the signatures sug-
gests that the reported expression signatures are highly heterogeneous. This heterogeneity
most likely reflects a diversity of patient populations or tumor specimens with regard to their
clinical and pathologic characteristics. It is also possible that some of the results were observed
by chance or from false-positive findings. To exclude this possibility, validation of the signature
genes in independent studies or distinct patient populations is necessary.
In our study of microarray expression data from 203 breast cancer patients, we analyzed the
genes present in multiple signatures, and found three genes (MAD2L1, PTTG1 and BUB1) sig-
nificantly associated with disease-free or overall survival. Of these genes, PTTG1 has been
investigated by Yoon et al. who demonstrated the possible biological relevance of the gene to
breast cancer [28]. No reports were found forMAD2L1 and BUB1. Based on the pathway
enrichment analysis of the genes involved in multiple expression signatures for prognosis, the
cell cycle pathway was suggested to be the most significantly enriched. All the three genes men-
tioned above are in this pathway.
Genes included in the expression signatures can be involved in multiple biological functions
and cellular activities. In the studies exploring gene expression profiles as signatures for sur-
vival outcomes, biological and pathologic relevance of the genes to cancer in the signatures are
often not evaluated experimentally and validated independently [33]. Breast cancer is a hetero-
geneous disease characterized by distinct pathologic features, disparate treatment responses,
and varied disease outcomes [34]. These differences may reflect specific gene expression signa-
tures. Using the genes in signatures, our pathway enrichment analysis showed that cell cycle is
the most significant pathway. As cell cycle involves the processes of cell growth and division,
and uncontrolled cell proliferation is a hallmark of cancer, [35, 36], it is not difficult to imagine
Table 2. Associations ofMAD2 and BUB1 expression with overall and relapse-free survival.
Variables Unadjusted Adjusted*
Overall Relapse-free Overall Relapse-free
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
MAD2L1
low 1 1 1 1
Mid 0.786 0.326 1.896 1.209 0.581 2.514 0.572 0.231 1.417 0.877 0.41 1.876
High 2.163 1.042 4.487 3.177 1.671 6.042 1.528 0.673 3.472 2.08 1.027 4.214
P for trend 0.0257 0.00016 0.223 0.0183
BUB1
low 1 1 1 1
Mid 1.269 0.501 3.216 2.067 0.996 4.289 1.214 0.439 3.355 1.652 0.744 3.67
High 3.263 1.459 7.298 3.378 1.691 6.746 2.543 0.96 6.734 2.329 1.037 5.231
P for trend 0.0019 0.00038 0.033 0.0054
* Adjusted for age at surgery, tumor grade, disease stage, ER status, and PR status.
doi:10.1371/journal.pone.0136246.t002
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why these signatures are predictive of disease prognosis. Thus, in this study, we focused on
MAD2L1 and BUB1, two critical mitotic checkpoint genes which play an important role in
the mitotic process. Our investigation showed that highMAD2L1 or BUB1 expression was
associated with poor prognosis of breast cancer, and moreover in vitro suppression of their
expression resulted in reduced cell proliferation and less aggressive cell behavior. In addition,
we found from publicly available data that expression ofMAD2L1 and BUB1 was higher in
tumor than in adjacent non-tumor tissues. Collectively, all of these observations suggest that
MAD2L1 and BUB1, two genes present in multiple gene expression signatures for breast cancer
prognosis, may be important molecules influencing tumor cell activity and patient survival.
Under normal physiologic circumstances, cell cycle is tightly controlled by several mecha-
nisms that regulate cell division and proliferation. One of the primary cell-cycle control mecha-
nisms is the mitotic checkpoints in mitosis [37]. As part of the mitotic checkpoints, theMAD
(mitotic arrest-deficient) and BUB (budding uninhibited by benzimidazole) gene families are
essential components of the spindle checkpoint, and were first identified by genetic screening
of budding yeast for mutants [38].MAD2L1 is required in mitosis when chromosomes are
Fig 2. Kaplan-Meier survival curves by different levels ofMAD2L1 and BUB1 expression in the GOBO
database. A) Overall survival (OS) by low, medium and highMAD2L1 expression; B) Relapse-free survival
(RFS) by low, medium and highMAD2L1 expression; C) Overall survival (OS) by low, medium and high
BUB1 expression; (D) Relapse-free survival (RFS) by low, medium and high BUB1 expression.
doi:10.1371/journal.pone.0136246.g002
MAD2L1 and BUB1 in Breast Cancer Progression
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unattached to the mitotic spindle that maintains chromosomal segregation, and is involved in
the spindle checkpoint during mitosis [39]. Dysregulation of these genes are associated with
chromosomal instability and substantial aneuploidy which occur often in cancer [40, 41]. One
study revealed that mRNA levels of many spindle checkpoint genes (MAD1L1,MAD2L1,
MAD2L2, BUB1, BUB1B, BUB3, CDC20 and TTK) were almost uniformly increased in breast
cancer cell lines relative to the levels in normal breast cells (MCF10A and primary mammary
gland); high expression was also observed in high-grade primary breast cancer [42]. In our
study, bothMAD2L1 and BUB1 were expressed substantially higher in high-grade than in low-
grade tumors. Our analysis ofMAD2L1 and BUB1 in two datasets (GSE37751 and GSE29044)
also demonstrated higher expression in breast cancer than in adjacent non-tumor tissues.
One review has pointed out that high levels of MAD2L1 or BUB1 could lead to the forma-
tion of aggressive tumors in multiple organs [43].MAD2L1 has been found to be overexpressed
in several types of tumor or cancer cell lines, including breast, lung, liver and stomach [44, 45].
Overexpression of BUB1 and other family members has been found to be associated with
tumor cell proliferation [46]. Transgenic mice overexpressing BUB1 developed various sponta-
neous tumors, and showed accelerated myc-induced lymphomagenesis [47]. High expression
of BUB1 was observed in a variety of human malignancies including gastric cancer [46, 48],
colorectal cancer [49], and lymphomas [50]. We and others found high expression ofMAD2L1
and BUB1 in breast cancer and their associations with unfavorable prognosis [2]. Although
mounting evidence suggests that highMAD2L1 or BUB1 are associated with tumor progres-
sion, study findings have been inconsistent. Reduced BUB1 expression was observed in a subset
of pancreatic cancer cells [51]. This inconsistency may arise from different expression in these
checkpoint components between actively proliferating cells and quiescent or differentiated
cells. Increased BUB1 expression accords with higher mitotic index in tumors compared to
neighboring tissues [47]. Alternatively, variation in function may reflect compensation for
other defects in the mitotic checkpoint.
In our in vitro experiments, we also observed that down-regulation of MAD2L1 or BUB1
expression resulted in reduced cell migration and invasion. The underlying mechanism for
these effects is unknown. One study showed that MAD2L1 was a direct transcriptional target
of E2F, and their interaction could cause retinoblastoma pathway dysregulation [52], which
may lead to the suppression of migration and invasion. Another recent study found that
knockdown of BUB1 could significantly inhibit the TGF-β-mediated induction of cell migra-
tion and invasion [53].
In summary, our study confirmed the prognostic value of two key mitotic checkpoint genes
MAD2L1 and BUB1, which have been included in multiple gene expression signatures for
breast cancer prognosis. We also found that these genes are biologically relevant to breast can-
cer progression, as suppression of their expression was associated with reduced tumor cell
growth, migration and invasion. Together, our investigation suggests that these genes may
serve as tumor markers for breast cancer prognosis as well as potential therapeutic targets to
suppress tumor growth.
Fig 3. Effects of MAD2L1 or BUB1 depletion on the phenotype of MDA-MB-231 cancer cells in vitro. A) MAD2L1 protein expression by western blot
analysis, β-actin used as control. B) Knockdown ofMAD2L1 expression inhibited cell proliferation. C) Knockdown ofMAD2L1 expression inhibited cell
migration. D) Knockdown ofMAD2L1 expression inhibited cell invasion. E) Representative pictures of cell migration and invasion before and after
knockdown. F) BUB1 protein expression by western blot analysis, β-actin used as control. G) Knockdown of BUB1 expression inhibited cell proliferation. H)
Knockdown of BUB1 expression inhibited cell migration. I) Knockdown of BUB1 expression inhibited cell invasion. J) Representative pictures of cell
migration and invasion before and after knockdown. * = P<0.001.
doi:10.1371/journal.pone.0136246.g003
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